Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy

Executive Summary

• Satellos Bioscience announced a peer‑reviewed Nature Communications paper confirming that Duchenne muscular dystrophy (DMD) originates from muscle stem cell dysfunction during fetal development.
• The study demonstrated that inhibiting AAK1 restores stem‑cell polarity, progenitor production, and normal muscle formation in dystrophin‑deficient models, supporting Satellos’s AAK1 inhibitor program (SAT‑3247).
• This validation provides strong preclinical evidence for SAT‑3247’s mechanism of action and reinforces the company’s differentiated approach to treating DMD.

Key Details

• Publication: “Intrinsic dysfunction in muscle stem cells lacking dystrophin begins during secondary myogenesis,” Nature Communications (online).
• Authors: Researchers from Ottawa Hospital Research Institute, including Satellos co‑founder & Chief Discovery Officer Dr. Michael Rudnicki.
• Key Findings:
• DMD stems from loss of polarity in muscle stem cells, leading to reduced myogenic progenitors and smaller fibers during fetal development.
• Pharmacologic blockade of AAK1 re‑establishes polarity, boosts progenitor generation, and normalizes muscle formation in dystrophin‑deficient models.
• Therapeutic Implication: Supports the potential of SAT‑3247 (oral small‑molecule AAK1 inhibitor) to restore muscle regeneration independent of dystrophin restoration or exon‑skipping strategies.
• Company Statement – Dr. Michael Rudnicki: Emphasized that DMD begins as a stem‑cell failure and that modulating AAK1 offers a powerful means to correct this defect.
• Company Statement – Frank Gleeson (CEO): Highlighted validation of the company’s conviction that correcting stem‑cell dysfunction can change DMD trajectory.
• SAT‑3247 Status: Currently in clinical development as a disease‑modifying treatment for DMD; the data bolster confidence in advancing the program.

Notable Quotes

“These findings make it abundantly clear that Duchenne begins as a failure of muscle stem cells to build and maintain muscle — without any evidence of myofiber fragility or damage.” – Dr. Michael Rudnicki, senior author.

“These findings further validate our conviction that correcting stem‑cell dysfunction is essential to changing the trajectory of Duchenne.” – Frank Gleeson, CEO.